#SFHS2614804AFrance approves six pharmaceutical products for public-sector use in defined obesity treatment cases
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds six pharmaceutical products to the list of medicines approved for use by public hospitals, local authorities, and other public services in France. Health insurance coverage is limited to adult obesity treatment where structured nutritional care has failed to produce at least 5% weight loss after six months. Coverage applies only alongside a reduced-calorie diet and increased physical activity, and only for patients with an initial BMI of 40 or higher, or 35 or higher with listed obesity-related conditions such as type 2 diabetes, treated hypertension, severe sleep apnea, chronic kidney disease, NASH or liver fibrosis, fertility issues linked to assisted reproduction, severe asthma related to obesity, disabling joint or back conditions, or other specified complications. Hospitals, prescribers, pharmacists, and reimbursement teams will need to check these eligibility limits before prescribing or billing.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds six pharmaceutical products to France’s approved list for use by public-sector healthcare and public services.
- Limits health insurance coverage to adult obesity treatment after failed structured nutritional care.
- Defines strict BMI and comorbidity criteria for reimbursement, including severe obesity or obesity with specified medical complications.
Obligations
What this law requires
Only provide health insurance coverage for the listed pharmaceutical specialties when used in adults after failure of properly conducted nutritional care, defined as less than 5% weight loss after six months.
Ensure covered use of the listed obesity medicines is only as an adjunct to a reduced-calorie diet and increased physical activity for weight loss and weight maintenance.
For adults without comorbidities, limit covered prescribing and reimbursement to patients with an initial BMI of at least 40 kg/m2.
For adults with comorbidities, limit covered prescribing and reimbursement to patients with an initial BMI of at least 35 kg/m2 and at least one qualifying obesity-related comorbidity listed in the order.
Do not treat isolated hepatic steatosis as a qualifying comorbidity for coverage of obesity drug treatment; NASH or hepatic fibrosis qualifies only under the stated conditions, including hepatologist agreement where specified.